ADHD

This article was originally published on Leafly.com and appears here with permission. A recent observational study conducted by a team of UK-based researchers found that medical cannabis may be beneficial for people with ADHD. In the rare study, researchers tracked specific cannabis...

Attention-deficit/hyperactivity disorder (ADHD) is one of the most commonly diagnosed psychiatric disorders in recent years, with an estimated global prevalence of 2.5% in adults and 5% in children. The condition causes trouble with maintaining attention,...

A recent study from the UK Medical Cannabis Registry has shed light on the potential benefits of cannabis-based medicinal products (CBMPs) in treating attention-deficit/hyperactivity disorder (ADHD). The research, focusing on health-related quality of life (HRQoL) and safety outcomes, indicates...

In the latest development of the criminal trial against FTX co-founder Sam Bankman-Fried, his legal team has sought court permission for their client to use ADHD medication during the trial to better focus. What Happened: As reported by Cointelegraph on Sunday, Bankman-Fried’s attorneys have...

Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF) recently formed a joint venture to develop novel plant-based medicines for mental health indications. They completed the import of Peruvian coca leaf to Canada to be assessed for the potential...

The shortage of stimulant-based ADHD (Attention Deficit Hyperactivity Disorder) medications like Adderall, Vyvanse and Ritalin persists, with leading drug makers unable to provide a solution. The shortage began in Fall 2022 and was exacerbated by record-high prescription rates. Teva...

This article was originally published on The Fresh Toast and appears here with permission. It’s important to know the potential adverse effects of weed before you run to your local dispensary and pick up a strain that’s supposed to help you focus. One of the most common and exaggerated...

This article was originally published on Psychedelic Spotlight and appears here with permission. If you fail to meet even one of the inclusion criteria, or you meet even one of the exclusion criteria, then you are not eligible and you will not be selected for participation. It seems like every week...

A biotech focused SPAC launched by frequent SPAC sponsor Chamath Palihapitiya announced a merger deal Wednesday morning. The SPAC Deal: Palihapitiya’s Social Capital Suvretta Holdings Corp I (NASDAQ: DNAA) announced a SPAC merger with Akili Interactive, valuing the company at an equity value...

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder. The company said it expects...

Cingulate Inc filed for an IPO, penciling in a modest $58 million raise, and expects to list on NASDAQ under CING ticker. Cingulate has a Phase 3-ready attention deficit hyperactivity disorder (ADHD) program in addition to a follow-up candidate soon to enter human trials and a...

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced Monday that its SPN-812 — a commercial treatment for patients with Attention Deficit Hyperactivity Disorder (ADHD), exhibited positive topline results in late-stage trials. What Happened Supernus claimed that the daily active...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Ehave, Inc. (OTCMKTS:EHVVF) is a provider of digital therapeutics, delivering evidence-based therapeutic interventions to patients. ...

Is cannabis a better alternative to ADHD drugs like Adderall or Ritalin? Robbin Lynn and Michele Ross explore the science behind why cannabis may be the healthier, more effective option. This video was originally posted on Green Flower.